The table below shows Amylyx Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$36.88M
-$39.82M
-$489.00K
-$5.07M
-$40.63M
-$12.64M
Capital expenditure
-
$11.00K
$67.00K
$250.00K
$342.00K
$14.00K
Investing cash flow
$36.26M
-$43.66M
$819.00K
$55.99M
-$99.31M
-$14.00K
Dividends paid
-
-
-
AMLX operating cash flow (10-K history)
Amylyx Pharmaceuticals, Inc. reported operating cash flow of -$123.34M for fiscal year 2025. That is up 26.4% from -$167.65M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$74.80M (FY 2021) to -$123.34M. Figures come from the company's audited annual reports as filed with the SEC.
